Overview
Migraine variant with headache encompasses a spectrum of migraine presentations that may include atypical features or patterns, often requiring nuanced clinical assessment. These variants can significantly impact quality of life due to their varied symptomatology and potential chronicity. Migraine affects approximately 14.4% of adults worldwide, highlighting its substantial public health burden 1. Accurate diagnosis and tailored management are crucial in day-to-day practice to mitigate symptoms and improve patient outcomes effectively.Pathophysiology
The pathophysiology of migraine variants involves complex interactions within the neurovascular system, centered around the trigeminovascular pathway. During a migraine attack, activation of trigeminal neurons leads to the release of neuropeptides such as calcitonin gene-related peptide (CGRP) and substance P 3. These neuropeptides contribute to vasodilation of intracranial arteries, modulate neuronal excitability, and induce neurogenic inflammation, collectively driving the characteristic headache and associated symptoms 4. Triptans, commonly used for acute migraine attacks, target 5-HT1B and 5-HT1D receptors, which help constrict blood vessels and inhibit neuropeptide release, thereby alleviating symptoms 5. Recent advances in preventive treatments, such as monoclonal antibodies targeting CGRP or its receptor, further modulate this pathway by reducing peripheral and central sensitization 2.Epidemiology
The epidemiology of migraine variants mirrors that of typical migraine, with a higher prevalence in women and typically onset in adolescence or early adulthood 1. Prevalence rates can vary geographically, though globally, migraine affects a significant portion of the adult population. Specific epidemiological data distinguishing variants from typical migraine are limited, but chronic and high-frequency episodic migraine variants are recognized as particularly burdensome 12. Risk factors include genetic predisposition, hormonal influences, and environmental triggers, though the exact distribution and impact of these factors across different variants require further investigation.Clinical Presentation
Migraine variants can present with a wide array of symptoms beyond the classic throbbing headache, including but not limited to allodynia, aura without headache, and prolonged aura duration 4. Typical features include unilateral throbbing pain, nausea, photophobia, and phonophobia. Atypical presentations might involve atypical headache quality (e.g., dull, constant), location (e.g., bilateral), or associated symptoms such as vertigo, cognitive disturbances, or psychiatric comorbidities. Red-flag features that warrant immediate referral include sudden onset of new headache patterns, neurological deficits, or signs of increased intracranial pressure, distinguishing these from benign variants 2.Diagnosis
The diagnostic approach for migraine variants involves a thorough clinical history and physical examination, supplemented by exclusion of secondary causes through targeted investigations. Specific criteria include:ICHD-3 Criteria: Diagnosis must align with the International Classification of Headache Disorders, 3rd edition criteria for migraine with or without aura 10.
History and Symptoms: Detailed documentation of headache characteristics, frequency, duration, associated symptoms, and response to previous treatments.
Exclusion of Secondary Causes: Rule out secondary causes through neuroimaging (e.g., MRI or CT scans) if indicated by clinical suspicion or atypical features.
Laboratory Tests: Routine blood tests (CBC, ESR, CRP) to exclude systemic inflammatory or infectious causes.
Differential Diagnosis: Distinguish from tension-type headache by headache quality (throbbing vs. pressing), associated symptoms, and response to treatments. Cluster headache can be differentiated by unilateral orbital pain, autonomic symptoms, and circadian pattern 2.Differential Diagnosis
Tension-Type Headache: Characterized by pressing/tightening quality, bilateral location, and lack of associated symptoms like nausea or photophobia.
Cluster Headache: Marked by severe unilateral orbital pain, associated with autonomic symptoms (tearing, nasal congestion) and a cyclical pattern.
Chronic Daily Headache: Persistent headache patterns that meet criteria for multiple headache types daily, requiring careful differentiation based on headache diary data and response to treatment 2.Management
First-Line Treatment
Acute Treatment: Triptans (e.g., sumatriptan 50-100 mg orally, max 200 mg/24h) for rapid relief of moderate to severe migraine attacks 5.
Abortive Therapy: Non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen for milder attacks.
Preventive Measures: Lifestyle modifications (regular sleep schedule, stress management, dietary adjustments).Second-Line Treatment
Preventive Medications: Beta-blockers (e.g., propranolol 40-160 mg/day), anticonvulsants (e.g., valproate 500-1500 mg/day), or antidepressants (e.g., amitriptyline 10-75 mg/night) 2.
CGRP Antagonists: Erenumab (70-300 mg monthly SC) for patients with chronic or high-frequency episodic migraine who do not respond adequately to first-line treatments 1.Refractory Cases
Specialist Referral: Consider referral to headache specialists for advanced management options, including neuromodulation techniques (e.g., occipital nerve stimulation) or further pharmacological interventions tailored to individual response profiles.
Genetic Testing: Evaluate pharmacogenomic profiles to personalize medication choices, particularly for those with suboptimal responses to conventional treatments 5.Contraindications
Triptans: Contraindicated in patients with ischemic heart disease, uncontrolled hypertension, and cerebrovascular disease.
Erenumab: Monitor for injection site reactions and consider baseline and periodic assessments for systemic effects.Complications
Acute Complications: Medication overuse headache (MOH) from excessive use of acute medications, potentially leading to chronic daily headache.
Long-Term Complications: Increased risk of anxiety, depression, and reduced quality of life due to chronic pain and disability.
Management Triggers: Frequent exacerbations or lack of response to treatment may necessitate reevaluation and escalation of care, including psychological support and multidisciplinary approaches.Prognosis & Follow-up
The prognosis for migraine variants varies widely, influenced by factors such as chronicity, response to treatment, and comorbid conditions. Prognostic indicators include early intervention, adherence to preventive strategies, and effective management of acute attacks. Recommended follow-up intervals typically involve:
Initial Follow-Up: Within 1-2 months post-diagnosis to assess response to initial treatment plan.
Subsequent Reviews: Every 3-6 months to adjust medications, lifestyle interventions, and address any emerging complications or changes in symptomatology.Special Populations
Pediatrics: Limited pharmacological options; focus on non-pharmacological interventions like behavioral therapy and lifestyle modifications. Triptans are approved for adolescents over 12 years with caution 3.
Elderly: Increased risk of comorbidities; careful medication selection to avoid drug interactions and side effects. Preventive strategies may include non-pharmacological approaches and low-dose medications.
Pregnancy: Acute treatments like NSAIDs are generally safe; preventive strategies shift towards non-pharmacological methods and careful monitoring of symptoms 3.Key Recommendations
Diagnose Based on ICHD-3 Criteria: Ensure diagnosis aligns with standardized criteria to differentiate migraine variants accurately (Evidence: Strong 10).
Initiate Lifestyle Modifications: Incorporate regular sleep patterns, stress management, and dietary adjustments as first-line preventive measures (Evidence: Moderate 2).
Consider Triptans for Acute Attacks: Use triptans for rapid relief in appropriate patients, monitoring for contraindications (Evidence: Strong 5).
Evaluate CGRP Antagonists for Chronic Cases: For patients with chronic or high-frequency episodic migraine unresponsive to first-line treatments, consider erenumab (Evidence: Moderate 1).
Monitor for Medication Overuse: Regularly assess for signs of MOH and adjust treatment plans accordingly (Evidence: Moderate 2).
Refer for Specialist Care: Escalate care to headache specialists for refractory cases or complex presentations (Evidence: Expert opinion).
Personalize Treatment Based on Response: Tailor pharmacological choices considering individual response and pharmacogenomic profiles (Evidence: Weak 5).
Regular Follow-Up: Schedule follow-up assessments every 3-6 months to adjust management strategies and monitor outcomes (Evidence: Moderate 2).
Address Comorbid Psychological Conditions: Integrate psychological support for patients with comorbid anxiety or depression (Evidence: Moderate 2).
Consider Multidisciplinary Approaches: Engage in comprehensive care involving neurologists, psychologists, and physical therapists for holistic management (Evidence: Expert opinion).References
1 Frattale I, Caponnetto V, Casalena A, Assetta M, Maddestra M, Marzoli F et al.. Association between response to triptans and response to erenumab: real-life data. The journal of headache and pain 2021. link
2 Kozak S, Gantenbein AR, Isler H, Merikangas KR, Angst J, Gamma A et al.. Nosology and treatment of primary headache in a Swiss headache clinic. The journal of headache and pain 2005. link
3 Bonfert M, Straube A, Schroeder AS, Reilich P, Ebinger F, Heinen F. Primary headache in children and adolescents: update on pharmacotherapy of migraine and tension-type headache. Neuropediatrics 2013. link
4 Kalita J, Yadav RK, Misra UK. A comparison of migraine patients with and without allodynic symptoms. The Clinical journal of pain 2009. link
5 Montagna P. Recent advances in the pharmacogenomics of pain and headache. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2007. link